Feds Bullard: Does not see policy changing under Powell

KTOS stock dips on insider sales, then rebounds. High P/E ratio remains a concern despite recent drops.

Medicare drug coverage plan may cost insurers billions, impacting premiums despite negotiated savings.

Simpson's 2.7% revenue growth & 4.8% EPS decline signal risk. Fair 19.3x P/E offers little upside.

Pharma stocks dip as Trump eyes 100% tariffs on some drugs. Investors eye valuation shifts.

Select Water Solutions surged 42% but trades at 44.7x P/E. Subscale biz, weak margins & FCF signal risk.

Tech ETF down 16% offers a discount. Diversified holdings mitigate risk, aiming for long-term recovery.

Kyndryl's 58% drop & negative ROIC signal risk despite cheap P/E. Avoid.